Abzena Emerges as a Leader in Antibody-Drug Conjugate Development According to Frost & Sullivan Report Abzena has been recognized by Frost & Sullivan as a top Antibody-Drug Conjugate CDMO, highlighting its innovative technologies and integrated approach in the biopharma industry.

Abzena Emerges as a Leader in Antibody-Drug Conjugate Development According to Frost & Sullivan Report #USA #San_Diego #antibody-drug_conjugate #Frost_&_Sullivan #Abzena

Strategic Alliance Between Abzena and Mabqi Promises Enhanced Biopharmaceutical Development Solutions Abzena and Mabqi have formed a strategic partnership that integrates antibody discovery with development solutions, streamlining biopharma services.

Strategic Alliance Between Abzena and Mabqi Promises Enhanced Biopharmaceutical Development Solutions #United_States #San_Diego #biopharmaceuticals #Abzena #Mabqi

Abzena Grants Exclusive Commercial License to Orion for Groundbreaking Antibody Targeting High Clinical Need Cancer Abzena has partnered with Orion to provide an exclusive commercial license for one of its antibodies, enhancing Orion's oncology pipeline significantly.

Abzena Grants Exclusive Commercial License to Orion for Groundbreaking Antibody Targeting High Clinical Need Cancer #USA #San_Diego #Abzena #Antibody_Licensing #Orion_Pharmaceuticals

Abzena Expands AbZelectPRO™ with Next-Gen GS Knockout Platforms for Enhanced Biopharma Solutions Abzena is enhancing its AbZelectPRO™ cell line development platform with new GS knockout systems aimed at optimizing biopharma collaboration and production.

Abzena Expands AbZelectPRO™ with Next-Gen GS Knockout Platforms for Enhanced Biopharma Solutions #United_States #San_Diego #Abzena #AbZelectPRO #ProteoNic

Geoffrey M. Glass Takes the Helm as CEO of Abzena, Promising Continued Growth Geoffrey M. Glass has assumed the role of CEO at Abzena, bringing over 30 years of experience. His leadership aims to continue the company's growth and client satisfaction.

Geoffrey M. Glass Takes the Helm as CEO of Abzena, Promising Continued Growth #USA #San_Diego #biopharmaceuticals #Abzena #Geoffrey_Glass

Abzena Launches Scientific Advisory Board to Propel Innovation in Biopharma Abzena has formed a Scientific Advisory Board to provide guidance and enhance innovation strategies in the biopharmaceutical industry, featuring prominent experts.

Abzena Launches Scientific Advisory Board to Propel Innovation in Biopharma #USA #San_Diego #Abzena #scientific_innovation #Biopharma_Advisory_Board

Discover the Latest Insights and Trends from the April 2025 Issue of Healthcare Digital The April 2025 edition of Healthcare Digital showcases exclusive insights from industry leaders and highlights the top procurement officers in healthcare.

Discover the Latest Insights and Trends from the April 2025 Issue of Healthcare Digital #London #United_Kingdom #Abzena #Healthcare_Digital #Arcutis_Biotherapeutics

Abzena Welcomes Taylor Boyd as New Chief Business Officer, Strengthening Leadership Team Abzena has appointed Taylor Boyd as Chief Business Officer, aiming to enhance corporate strategies and foster innovation in biologics.

Abzena Welcomes Taylor Boyd as New Chief Business Officer, Strengthening Leadership Team #United_States #San_Diego #CDMO #Abzena #Taylor_Boyd

Abzena Welcomes Dr. Moncef Slaoui to Its Board to Drive Innovation in Biopharma Abzena has appointed Dr. Moncef Slaoui to its Board, enhancing its leadership team with expertise in biopharmaceutical innovation and growth.

Abzena Welcomes Dr. Moncef Slaoui to Its Board to Drive Innovation in Biopharma #USA #San_Diego #Biopharma #Abzena #Dr._Slaoui